Cargando…
hERG Potassium Channel Blockade by the HCN Channel Inhibitor Bradycardic Agent Ivabradine
BACKGROUND: Ivabradine is a specific bradycardic agent used in coronary artery disease and heart failure, lowering heart rate through inhibition of sinoatrial nodal HCN‐channels. This study investigated the propensity of ivabradine to interact with KCNH2‐encoded human Ether‐à‐go‐go–Related Gene (hER...
Autores principales: | Melgari, Dario, Brack, Kieran E., Zhang, Chuan, Zhang, Yihong, El Harchi, Aziza, Mitcheson, John S., Dempsey, Christopher E., Ng, G. André, Hancox, Jules C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579960/ https://www.ncbi.nlm.nih.gov/pubmed/25911606 http://dx.doi.org/10.1161/JAHA.115.001813 |
Ejemplares similares
-
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide
por: Melgari, Dario, et al.
Publicado: (2015) -
Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration
por: Melgari, Dario, et al.
Publicado: (2014) -
Inhibition of the hERG Potassium Channel by a Methanesulphonate-Free E-4031 Analogue
por: Helliwell, Matthew V., et al.
Publicado: (2023) -
Ranolazine inhibition of hERG potassium channels: Drug–pore interactions and reduced potency against inactivation mutants
por: Du, Chunyun, et al.
Publicado: (2014) -
The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine
por: El Harchi, Aziza, et al.
Publicado: (2020)